BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 35884585)

  • 1. Novel Salvage Therapy Options for Initial Treatment of Relapsed/Refractory Classical Hodgkin's Lymphoma: So Many Options, How to Choose?
    Takiar R; Karimi Y
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
    O'Connor OA; Lue JK; Sawas A; Amengual JE; Deng C; Kalac M; Falchi L; Marchi E; Turenne I; Lichtenstein R; Rojas C; Francescone M; Schwartz L; Cheng B; Savage KJ; Villa D; Crump M; Prica A; Kukreti V; Cremers S; Connors JM; Kuruvilla J
    Lancet Oncol; 2018 Feb; 19(2):257-266. PubMed ID: 29276022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.
    Moskowitz AJ; Schöder H; Yahalom J; McCall SJ; Fox SY; Gerecitano J; Grewal R; Hamlin PA; Horwitz S; Kobos R; Kumar A; Matasar M; Noy A; Palomba ML; Perales MA; Portlock CS; Sauter C; Shukla N; Steinherz P; Straus D; Trippett T; Younes A; Zelenetz A; Moskowitz CH
    Lancet Oncol; 2015 Mar; 16(3):284-92. PubMed ID: 25683846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma.
    Desai SH; Spinner MA; David K; Bachanova V; Goyal G; Kahl B; Dorritie K; Azzi J; Kenkre VP; Arai S; Chang C; Fusco B; Sumransub N; Hatic H; Saba R; Ibrahim U; Harris EI; Shah H; Murphy J; Ansell S; Jagadish D; Orellana-Noia V; Diefenbach C; Iyenger S; Rappazzo KC; Mishra R; Choi Y; Nowakowski GS; Advani RH; Micallef IN
    Am J Hematol; 2023 Mar; 98(3):464-471. PubMed ID: 36629030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of pembrolizumab versus brentuximab vedotin for patients with relapsed or refractory classical Hodgkin's lymphoma: a United States payer perspective.
    Large S; Hettle R; Balakumaran A; Wu E; Borse RH
    J Med Econ; 2018 Nov; ():1-10. PubMed ID: 30303022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relapsed and Refractory Classical Hodgkin Lymphoma: Keeping Pace With Novel Agents and New Options for Salvage Therapy.
    Moskowitz AJ; Herrera AF; Beaven AW
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():477-486. PubMed ID: 31099645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Moskowitz CH; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Gianni AM; Carella A; Osmanov D; Bachanova V; Sweetenham J; Sureda A; Huebner D; Sievers EL; Chi A; Larsen EK; Hunder NN; Walewski J;
    Lancet; 2015 May; 385(9980):1853-62. PubMed ID: 25796459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequencing novel agents in the treatment of classical Hodgkin lymphoma.
    Ferhanoglu B; Ozbalak M
    Expert Rev Hematol; 2023; 16(12):991-1015. PubMed ID: 37897182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Therapies in the Treatment of Hodgkin Lymphoma.
    Andrade-Gonzalez X; Ansell SM
    Curr Treat Options Oncol; 2021 Mar; 22(5):42. PubMed ID: 33755826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in CD30- and PD-1-targeted therapies for relapsed or refractory Hodgkin lymphoma.
    Ma H; Li X; Lin M; Lv K; Zhang M; Wu X
    Am J Transl Res; 2021; 13(11):12206-12216. PubMed ID: 34956447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation.
    Kaloyannidis P; Hertzberg M; Webb K; Zomas A; Schrover R; Hurst M; Jacob I; Nikoglou T; Connors JM
    Br J Haematol; 2020 Feb; 188(4):540-549. PubMed ID: 31588564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies.
    Vassilakopoulos TP; Chatzidimitriou C; Asimakopoulos JV; Arapaki M; Tzoras E; Angelopoulou MK; Konstantopoulos K
    Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31362369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma.
    Voorhees TJ; Beaven AW
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33050054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience.
    Massaro F; Pavone V; Stefani PM; Botto B; Pulsoni A; Patti C; Cantonetti M; Visentin A; Scalzulli PR; Rossi A; Galimberti S; Cimminiello M; Gini G; Musso M; Sorio M; Arcari A; Zilioli VR; Luppi M; Mannina D; Fabbri A; Pietrantuono G; Annibali O; Tafuri A; Prete E; Mulè A; Barbolini E; Marcheselli L; Luminari S; Merli F
    Hematol Oncol; 2022 Feb; 40(1):31-39. PubMed ID: 34694649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.
    Taçyıldız N; Tanyıldız HG; Ünal E; Dinçaslan H; Asarcıklı F; Aksoy BA; Vatansever G; Yavuz G
    Turk J Pediatr; 2019; 61(5):671-676. PubMed ID: 32104998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy.
    Randall MP; Spinner MA
    Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
    Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL;
    Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis.
    Massaro F; Meuleman N; Bron D; Vercruyssen M; Maerevoet M
    Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
    Younes A; Santoro A; Shipp M; Zinzani PL; Timmerman JM; Ansell S; Armand P; Fanale M; Ratanatharathorn V; Kuruvilla J; Cohen JB; Collins G; Savage KJ; Trneny M; Kato K; Farsaci B; Parker SM; Rodig S; Roemer MG; Ligon AH; Engert A
    Lancet Oncol; 2016 Sep; 17(9):1283-94. PubMed ID: 27451390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent COVID-19 Infection in a Refractory/Classical Hodgkin's Lymphoma Patient Undergoing Autologous Stem Cell Transplantation: A Case Report.
    Hamed M; Alamoudi D
    Cureus; 2023 Oct; 15(10):e46950. PubMed ID: 38022277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.